Back to search
Monoclonal Gammopathy of Renal Significance
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Monoclonal Gammopathy of Renal Significance trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Monoclonal Gammopathy of Renal Significance trials you may qualify forThe purpose of this study is to find out whether cyclophosphamide, bortezomib, dexamethasone (CyBorD) with daratumumab SC is a safe treatment combination for MG…
The purpose of this study is to see whether Isatuximab can help improve kidney function of participants with MGRS. Isatuximab is approved by the Food and Drug A…
The goal of this clinical trial is to learn if drug daratumumab works to treat kidney diseases other than AL-amyloidosis that fall under the category of monoclo…
This is an open-label, multicenter, Phase 2 study in subjects with newly diagnosed monoclonal immunoglobulin deposition disease treated with daratumumab, bortez…
The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research. The purpo…
The primary aim is to establish a prospective cohort of patients with plasma cell disorders (PCDs). All of the hospitalized PCD patients who are willing to sign…
This is an open-label, multicenter, phase 2 study in subjects with newly diagnosed proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGN…
The term "Monoclonal Gammopathies of Renal Significance" (MGRS) describes a group of diseases characterized by the presence of an immunoglobulin or monoclonal i…
This is the first prospective study which evaluate patients with small B-cell clones to diagnose monoclonal gammopathy of renal significance (MGRS) and characte…